2016_Head & Neck COURSE BOOK
Pembrolizumab Anti-PD-1
Total N=117
HPV+ N=34
HPV- N=81
ORR
24.8%
20.6%
27.2%
MEDI4736 Anti-PD-L1
Total N=62
PD-L1+ N=22
PD-L1- N=37
ORR
11%
18%
8%
Seiwert et al, ASCO 2015
Made with FlippingBook
Pembrolizumab Anti-PD-1
Total N=117
HPV+ N=34
HPV- N=81
ORR
24.8%
20.6%
27.2%
MEDI4736 Anti-PD-L1
Total N=62
PD-L1+ N=22
PD-L1- N=37
ORR
11%
18%
8%
Seiwert et al, ASCO 2015
Made with FlippingBook